{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:14:15Z","timestamp":1792239255278,"version":"4.4.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic lymphocytic leukemia (CLL) is a quiescent B-cell malignancy that depends on transcriptional dysregulation for survival. The histone deacetylases are transcriptional regulators whose role within the regulatory chromatin and consequence on the CLL transcriptome is poorly characterized. Here, we profiled and integrated the genome-wide occupancy of HDAC1, BRD4, H3K27Ac, and H3K9Ac signals with chromatin accessibility, Pol2 occupancy, and target expression signatures in CLL cells. We identified that when HDAC1 was recruited within super-enhancers (SEs) marked by acetylated H3K27 and BRD4, it functioned as a transcriptional activator that drove the de novo expression of select genes to facilitate survival and progression in CLL. Targeting HDACs reduced BRD4 and Pol2 engagement to downregulate the transcript and proteins levels of specific oncogenic driver genes in CLL such as BLK, a key mediator of the B-cell receptor pathway, core transcription factors such as PAX5 and IKZF3, and the antiapoptotic gene, BCL2. Concurrently, HDAC1, when recruited in the absence of SEs, repressed target gene expression. HDAC inhibition reversed silencing of a defined set of protein-coding and noncoding RNA genes. We focused on a specific set of microRNA genes and showed that their upregulation was inversely correlated with the expression of CLL-specific survival, transcription factor, and signaling genes. Our findings identify that the transcriptional activator and repressor functions of HDACs cooperate within the same tumor to establish the transcriptional dependencies essential for survival in CLL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007998","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T14:17:18Z","timestamp":1666793838000},"page":"2897-2911","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"7","author":[{"given":"Tzung-Huei","family":"Lai","sequence":"first","affiliation":[{"name":"1Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-8051","authenticated-orcid":false,"given":"Hatice Gulcin","family":"Ozer","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Informatics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-8845","authenticated-orcid":false,"given":"Pierluigi","family":"Gasparini","sequence":"additional","affiliation":[{"name":"3Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8880-4334","authenticated-orcid":false,"given":"Giovanni","family":"Nigita","sequence":"additional","affiliation":[{"name":"3Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7241-7751","authenticated-orcid":false,"given":"Rosario","family":"Distefano","sequence":"additional","affiliation":[{"name":"3Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianbo","family":"Yu","sequence":"additional","affiliation":[{"name":"4Center for Biostatistics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Ravikrishnan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2954-0305","authenticated-orcid":false,"given":"Selen","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Informatics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9421-367X","authenticated-orcid":false,"given":"Juan","family":"Gallegos","sequence":"additional","affiliation":[{"name":"5Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-3584","authenticated-orcid":false,"given":"Sachet","family":"Shukla","sequence":"additional","affiliation":[{"name":"5Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-9500","authenticated-orcid":false,"given":"Vinay","family":"Puduvalli","sequence":"additional","affiliation":[{"name":"6Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Woyach","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lapalombella","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-5562","authenticated-orcid":false,"given":"James","family":"Blachly","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, The University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-8436","authenticated-orcid":false,"given":"Deepa","family":"Sampath","sequence":"additional","affiliation":[{"name":"5Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"issue":"26","key":"2023062614232933400_bib1","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2016-07-727750","article-title":"Targeting BTK through microRNA in chronic lymphocytic leukemia","volume":"128","author":"Bottoni","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2023062614232933400_bib2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2023062614232933400_bib3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2023062614232933400_bib4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"2023062614232933400_bib5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A\u00a0microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023062614232933400_bib6","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2023062614232933400_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023062614232933400_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023062614232933400_bib9","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023062614232933400_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023062614232933400_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023062614232933400_bib12","doi-asserted-by":"crossref","first-page":"14690","DOI":"10.1038\/s41598-018-32927-9","article-title":"Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in\u00a0vivo","volume":"8","author":"Kelly","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"2023062614232933400_bib13","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood-2011-05-351510","article-title":"Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia","volume":"119","author":"Sampath","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2023062614232933400_bib14","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/15592294.2014.969628","article-title":"Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients","volume":"9","author":"Van Damme","year":"2014","journal-title":"Epigenetics"},{"issue":"1","key":"2023062614232933400_bib15","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1038\/s41467-019-11046-7","article-title":"Chemical genomics reveals histone deacetylases are required for core regulatory transcription","volume":"10","author":"Gryder","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"2023062614232933400_bib16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.celrep.2015.10.013","article-title":"Histone deacetylases positively regulate transcription through the elongation machinery","volume":"13","author":"Greer","year":"2015","journal-title":"Cell Rep"},{"issue":"6","key":"2023062614232933400_bib17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ccell.2018.11.001","article-title":"Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia","volume":"34","author":"Ott","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"2023062614232933400_bib18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-17-0902","article-title":"BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor","volume":"8","author":"Ozer","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"2023062614232933400_bib19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-05-0442","article-title":"CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in\u00a0vitro and in\u00a0vivo","volume":"5","author":"Buggy","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2023062614232933400_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ebiom.2019.10.061","article-title":"Integrated miRNA and mRNA expression profiling identifies novel targets and pathological mechanisms in autoimmune thyroid diseases","volume":"50","author":"Martinez-Hernandez","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"2023062614232933400_bib21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2014-03-559690","article-title":"MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia","volume":"124","author":"Cui","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2023062614232933400_bib22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood-2010-01-263889","article-title":"microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival","volume":"116","author":"Rossi","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2023062614232933400_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.2010.1919","article-title":"Association of a microRNA\/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia","volume":"305","author":"Fabbri","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"2023062614232933400_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MOH.0000000000000048","article-title":"Targeting the B-cell receptor signaling pathway in B lymphoid malignancies","volume":"21","author":"Buchner","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"8","key":"2023062614232933400_bib25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023062614232933400_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/10428194.2019.1691194","article-title":"Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2023062614232933400_bib27","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: Emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"2023062614232933400_bib28","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","article-title":"First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors","volume":"25","author":"Piha-Paul","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2023062614232933400_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2020.05.008","article-title":"The novel dual BET\/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells","volume":"486","author":"Laszig","year":"2020","journal-title":"Cancer Lett"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2897\/2060193\/blooda_adv-2022-007998-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2897\/2060193\/blooda_adv-2022-007998-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T14:26:28Z","timestamp":1687789588000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/12\/2897\/486881\/HDAC1-regulates-the-chromatin-landscape-to-control"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007998","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}